Journal
FUTURE MEDICINAL CHEMISTRY
Volume 3, Issue 4, Pages 437-450Publisher
FUTURE SCI LTD
DOI: 10.4155/FMC.10.292
Keywords
-
Categories
Funding
- Austrian Science Fund (FWF) [P 23051] Funding Source: researchfish
- Austrian Science Fund FWF [P 24587] Funding Source: Medline
Ask authors/readers for more resources
Background: The pathogenicity of influenza A and B viruses depends on the function of influenza neuraminidase (NA). Emerging resistant influenza A viruses of subtype H1N1 increasingly challenge the effectiveness of established NA inhibitors. Recent computational studies have indicated several weak points of NA that can be exploited for rational inhibitor design to conquer this imminent threat, such as the opening of the binding pocket due to the flexibility of the 150-, 245- and 430-loops. Methods: We employed shape-focused virtual screening based on a recently discovered lead compound, katsumadain A, to identify novel promising compounds with significant inhibitory efficacy on NA and resistance-breaking capacity on oseltamivir-resistant strains. A potential binding mode of these compounds was derived employing ligand-based techniques and protein-ligand docking using representative protein conformations selected from molecular dynamics simulations. Results: Five novel compounds were identified by virtual screening. Their IC50 values, determined in chemiluminescence-based NA inhibition assays, are in the range of 0.18-17 mu M. In particular, artocarpin exhibits high affinity toward three H1N1 oseltamivir-sensitive influenza A viruses. It also inhibits the NA of an oseltamivir-resistant H1N1 isolate.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available